Epistem Ltd. is a leading contract service provider offering innovative preclinical research services, genetic and protein biomarker testing as well as histology services to pharmaceutical, biotech and academic customers to support to drug discovery and development pipelines. We have worked with over 200 pharmaceutical and biotechnology companies at both preclinical and clinical stages. Our high level of expertise and customer focus has led to an enviable track record and impressive amount of repeat business. Our preclinical contract research services group advance drug development programs for oncology, inflammatory, dermatology, auto-immune and GI disease indications. We offer an impressive range of preclinical models in these therapeutic areas. We also provide information relating to toxicity assessments and are experts in GI tox. We also offer a broad range of cell based assays including novel stem cell assays. Our biomarker services division offers GCLP compliant genetic testing, histology, FACS analysis and protein biomarker detection. Epistem’s genetics group offer gene expression and DNA genotyping sample analysis by NGS, microarray and qPCR. We specialise in working with small starting materials (down to a single cell input) applying our proprietary low input techniques and products to support drug development programs. We are specialists in fractionating cell populations and conducting genetic analysis. We have pioneered techniques using plucked scalp hair and laser capture microdissected material to provide gene expression biomarker information to drug development programs. Epistem is committed to provide reliable and innovative services to support all phases of drug development from to preclinical projects to clinical trials. Website: www.epsitem.co.uk
